Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-11-23 Regulatory Filings
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (1768 characters) submitted to the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states 'Attached hereto is a report on Interested party transaction' and provides a filename (20251121Form4_isa.pdf). Per the 'Menu vs Meal' rule, since this is a short announcement notifying the public of an attached report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing Classification · 100% confidence The document is a Form 4 filed with the U.S. Securities and Exchange Commission (SEC), which reports changes in beneficial ownership of securities by company insiders such as directors, officers, or significant shareholders. It includes detailed tables of securities acquired or disposed of, dates, prices, and ownership relationships. The presence of Form 4 and the nature of the content clearly indicate this is a Director's Dealing report, which is used to disclose insider transactions. The document length and content confirm it is not a brief announcement or a certification but the actual filing of insider transactions.
2025-11-20 Hebrew (modern)
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing Classification · 98% confidence The document is a short notification (1768 characters) filed with the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Interested party transactoin' and provides a filename '20251120Form4_isa.pdf'. According to the 'Menu vs Meal' rule, since this is a short announcement regarding the publication/attachment of another document, it is classified as a Report Publication Announcement (RPA).
2025-11-20 English
OPKO Health to participate in the Piper Sandler 37th Annual Healthcare Conference.
Regulatory Filings Classification · 95% confidence The document is a short announcement about OPKO Health's participation in an upcoming healthcare conference, specifically the Piper Sandler 37th Annual Healthcare Conference. It mentions management's planned activities such as one-on-one meetings and a fireside discussion. There is no financial data, no report attached or referenced as being published, and no regulatory or compliance content. The document is clearly an investor relations event announcement rather than a financial report, regulatory filing, or other specific filing type. Given the content and length (1114 characters), it does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2025-11-20 Hebrew (modern)
OPKO Health to participate in the Piper Sandler 37th Annual Healthcare Conference.
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 2,000 characters) that serves as a notification to the Israel Securities Authority regarding the company's participation in an upcoming conference. It explicitly states 'Attached hereto is a report on OPKO Health to participate in the Piper Sandler 37th Annual Healthcare Conference' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, this is an announcement of a report/presentation rather than the presentation itself, making it a Report Publication Announcement (RPA).
2025-11-20 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- PHILLIP FROST
Director's Dealing Classification · 100% confidence The document is a U.S. Securities and Exchange Commission Form 4, which is a mandatory filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). The content explicitly lists transactions (purchases of common stock) by Phillip Frost, M.D., for OPKO Health, Inc. This falls under the category of Director's Dealing.
2025-11-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.